Si D, et al. - Researchers assessed the expression of cluster of differentiation 44 (CD44) in glioblastoma multiforme (GBM). From 62 GBM patients, they obtained tissue specimens in order to determine CD44 expression, and a follow-up of prognosis was performed. High CD44 staining was noted in 38.7% (24/62) of the patients. For high and low expressions of CD44, the median survival times were estimated to be 3.5 months and 18.5 months, respectively. A link with the overall survival time of GBM patients was demonstrated by tumor location, the extent of tumor resection, adjuvant chemotherapy, and CD44 expression, as revealed in Kaplan-Meier analysis. Independent unfavorable prognostic factors for GBM patients, as revealed in multivariate analysis, were non-usage of adjuvant chemotherapy and CD44 overexpression. According to the findings, a high expression of CD44 behaves like a poor prognosis indicator in GBM patients.